Company / Capital Returned to Shareholders
Roivant Sciences Capital Returned to Shareholders History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$1.3B
FY2024
5-year range
$0 / $1.3B
FY2023-FY2024
Trend
-
vs FY2023
Sector context
#10 of 52
Health Care
What the data says
Roivant Sciences's capital returned to shareholders of $1.3B is higher than 81% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$1.3B in FY2024. Top quartile in the Health Care sector.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 52This company $1.3B Sector average $1.3B
▼
-3.1% below sector average
Key checks
Key Insights
- Ranks #10 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.3B | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026